EHV insertion site ORF70

Patent metadata

Field	Value
Publication number	US-10619169-B2
Application number	US-201715706889-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 20, 2016
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site ORF70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

First claim

What is claimed is:

1. An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising an expression cassette comprising an exogenous nucleotide sequence of interest, wherein said nucleotide sequence of interest inserted into ORF70 in an EHV-1 vector (ORF70) and operably linked to a promoter sequence, and a left ORF70 flanking region selected from the group consisting of sequences having at least 95% homology with any of SEQ ID Nos: 13, 15, and 17, and a right ORF70 flanking region selected from the group consisting of sequences having at least 95% homology with any of SEQ ID Nos: 14, 16, and 18.

2. The EHV-1 vector of claim 1 , wherein the ORF70 has a partial deletion, truncation, substitution, or modification, and wherein ORF71 remains functional.

3. The EHV-1 vector of claim 1 , wherein ORF70 possesses an approximately 801 bp deletion corresponding to SEQ ID NO.: 20 or a sequence having at least 95% sequence homology with SEQ ID NO.: 20.

4. The EHV-1 vector of claim 1 , wherein the EHV-1 vector comprises (i) at least one left ORF70 flanking region selected from the group consisting of: SEQ ID NO.: 13, SEQ ID NO.: 15, and SEQ ID NO.: 17, and (ii) at least one right ORF70 flanking region selected from the group consisting of: SEQ ID NO.: 14, SEQ ID NO.: 16, and SEQ ID NO.: 18.

5. The EHV-1 vector of claim 1 , wherein said nucleotide sequence of interest is recombinant.

6. The EHV-1 vector of claim 1 , wherein said nucleotide sequence of interest is recombinant and/or heterologous.

7. The EHV-1 vector of claim 1 , wherein said nucleotide sequence of interest is an antigen encoding sequence related to a pathogen infecting a food producing animal such as swine or cattle.

8. The EHV-1 vector of claim 1 , further comprising additional regulatory sequences such as a termination signal or polyadenylation sequence.

9. The EHV-1 vector of claim 1 , wherein the promoter sequence operably linked to the nucleotide sequence of interest is selected from the group consisting of: SV40 large T, HCMV and MCMV immediate early gene 1, human elongation factor alpha promoter, baculovirus polyhedrin promoter, a sequence having at least 95% sequence identity with any one of SEQ ID Nos.: 1, 2, 3, and 4 or the complementary sequences thereof.

10. A mammalian host cell characterized in that it comprises a vector according to claim 1 .

11. A method comprising manufacturing an immunogenic composition or vaccine using the vector according to claim 1 .

12. A method for the preparation of an immunogenic composition or a vaccine for reducing the incidence or the severity of one or more clinical signs associated with or caused by an infection, comprising the following steps:
a. Infecting a mammalian host cell with the vector according to claim 1 ,
b. cultivating the infected cells under suitable conditions,
c. collecting infected cell cultures,
d. optionally purifying the collected infected cell cultures of step c)
e. optionally mixing said collected infected cell culture with a pharmaceutically acceptable carrier.

13. An immunogenic composition comprising the EHV-1 RacH vector according to claim 1 .

14. An immunogenic composition comprising
a. the vector according to claim 1 , and/or
b. a polypeptide expressed by the vector according to claim 1 , such as a virus, a modified live virus, a virus like particle (VLP), and
c. optionally a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is suitable for oral, intradermal, intramuscular or intranasal application, and
said immunogenic composition comprises a virus, such as an infectious virus.

15. A vaccine or pharmaceutical composition comprising
a. the vector according to claim 1 , and/or
b. a polypeptide expressed by the vector according to claim 1 , selected from the group consisting of a modified live virus, a virus like particle (VLP), and
c. a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is suitable for oral, intradermal, intramuscular or intranasal application, and
optionally said vaccine further comprises an adjuvant.

16. An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising an exogenous nucleotide sequence of interest, wherein said nucleotide sequence of interest is operably linked to a promoter sequence, and a left ORF70 flanking region selected from the group consisting of: SEQ ID NOs.: 13, 15, and 17, and a right ORF70 flanking region selected from the group consisting of: SEQ ID Nos.: 14, 16, and 18.

17. An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising a nucleotide sequence of interest inserted into ORF70.

18. An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising a first and a second nucleotide sequence or gene of interest inserted into ORF70.

19. The EHV-1 vector of claim 17 , wherein the gene of interest is operably linked to a regulatory sequence, such as a promoter sequence.

20. The EHV-1 vector of claim 18 , wherein promoter sequences are operably linked to the first and second nucleotide sequence or gene of interest, and wherein said promoter sequences are different.

21. The EHV-1 vector of the claim 18 , wherein the promoter sequence operably linked to the first nucleotide sequence or gene of interest of interest is p455 (SEQ ID NO. 4) or a sequence having at least 95% sequence identity with SEQ ID Nos.: 4 or the complementary sequence thereof, and wherein the promoter sequence operably linked to the second nucleotide sequence or gene of interest of interest is p430 (SEQ ID NO. 3) or a sequence having at least 95% sequence identity with SEQ ID Nos.: 3 or the complementary sequence thereof.

22. A method of reducing or preventing the clinical signs or disease caused by an infection with a pathogen in an animal or for treating or preventing an infection with a pathogen in an animal, comprising administering to the animal the immunogenic composition according to claim 14 , wherein said animal is a food producing animal such as swine.

23. A method of immunizing an animal such as a food producing animal including swine against a clinical disease caused by a pathogen in said animal, said method comprising the step of administering to the animal the immunogenic composition according to claim 14 , whereby said immunogenic composition or vaccine fails to cause clinical signs of infection but is capable of inducing an immune response that immunizes the animal against pathogenic forms of said pathogen.

24. A kit for vaccinating an animal, such as swine or cattle, against a disease associated with and/or reducing the incidence or the severity of one or more clinical signs associated with or caused by a pathogen in an animal comprising:
a) a dispenser capable of administering a vaccine to said animal; and
b) the immunogenic composition according to claim 14 , and
c) optionally an instruction leaflet.

Assignees

• Boehringer Ingelheim Vetmedica Gmbh

Inventors

• Mundt Alice
• Gallei Andreas
• REHMET Kristina

Classifications

• A61K2039/70

  Multivalent vaccine · CPC title

• C12N2760/16111

  Influenzavirus A, i.e. influenza A virus · CPC title

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• C12N2710/16734

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title